List view / Grid view
Dr Owen Seddon, Consultant in Infectious Diseases and Medical Microbiology at University Hospital of Wales, explains how successes in the development of the coronavirus vaccine must be used in the fight against other vaccine preventable disease.
Targeting medicines against the genetic and molecular drivers of lung, breast and other tumours has helped transform cancer care for many patients, yet precision medicine for complex chronic diseases has lagged behind. Maria Orr, Adam Platt and Ben Challis, from BioPharmaceuticals R&D at AstraZeneca, explain why this is changing for…
The results indicate that mRNA-1273.211 at the 50 µg dose level induced higher antibody responses than the 50 µg mRNA-1273 booster, even when additional variants of concern were not included in the booster vaccine.
The new chemical reaction, a carbon-hydrogen amination cross-coupling reaction, creates a faster, simpler way of making tertiary amines without the inherent limitations of classic methods.
IRBM’s goal will be to help ensure a more resilient global response to future epidemics by producing second generation vaccines and treatments for SARS-CoV-2 and new coronaviruses.
Most therapeutic approaches in immuno-oncology focus on targeting the adaptive immune system; innate immunity has only recently gathered momentum. One of the most potent receptors for activating innate immune cells such as natural killer cells and macrophages is CD16A. Addressing this target mimics the body’s natural defense against potential threats,…
Phase III trial shows Evusheld (tixagevimab and cilgavimab) significantly reduces the risk of developing symptomatic COVID-19 in vulnerable populations.
The results of a recent international study suggest that left-handed gold nanoparticles can increase vaccine effectiveness by 25 percent, providing useful adjuvant capabilities.
Features in this in-depth focus highlight developments in the MRI contrast agent space, explore the development of precision medicine for chronic diseases and explain why immunotherapies should engage the innate immune system in the fight against cancer.
GlaxoSmithKline has announced the agreed $1.9bn acquisition of biopharmaceutical company Sierra Oncology, which specialises in treatments for rare forms of cancer.
Features in this issue discuss how bioprocessing must adapt to meet the needs of autologous cell therapies, the role of mass spectrometry in enhancing antibody consistency and the economic benefits of embracing continuous manufacturing. Also in this journal, articles exploring the development of precision medicine for chronic diseases, why acoustic…
Water content determination of Ibuprofen tablets with an automated Karl Fischer titrator coupling with gas phase extraction.
The new clinical trial guidance asks sponsors to submit a Race and Ethnicity Diversity Plan outlining how they plan to enrol participants from underrepresented populations.
Pzifer's acquisition of ReViral will include its portfolio of promising therapeutic candidates, such as sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host cell.
New Ultomiris (ravulizumab-cwvz) follow-up data shows sustained functional improvements in certain adults with generalised myasthenia gravis (gMG).
